Q-omics provides the consensus-scored TMEM39A profile across patient tissues and cancer cell-line models. TMEM39A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM39A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TMEM39A RNA expression shows 19,433 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where TMEM39A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM39A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM39A survival associations across molecular data types. TMEM39A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM39A RNA expression–survival associations across cancer types. High TMEM39A expression shows unfavorable associations in KIRP, LIHC, ACC, COAD and LGG, but favorable associations in SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM39A RNA expression.
This table summarizes TMEM39A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM39A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM39A shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, KIRC, BLCA and LIHC. The HNSC box plot shows higher TMEM39A RNA expression in tumor versus normal tissue (log2 FC = +1.354, t-test p < 0.001).
This table shows molecular features associated with TMEM39A in patient tissues and cancer cell lines. In patient samples, TMEM39A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM39A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
